Creative Diagnostics Launches Human Hybrid IgM Control Monoclonal Antibodies to Accelerate Diagnostic Assay Development

June 23, 2025 11:00 PM AEST | By EIN Presswire
 Creative Diagnostics Launches Human Hybrid IgM Control Monoclonal Antibodies to Accelerate Diagnostic Assay Development
Image source: EIN Presswire

Creative Diagnostics releases its new Human Hybrid IgM Control Monoclonal Antibodies for research applications.

NEW YORK, NY, UNITED STATES, June 23, 2025 /EINPresswire.com/ -- Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced release of its new line of Human Hybrid IgM Control Monoclonal Antibodies for research applications, covering a range of diseases such as CMV, HSV, MeV, MuV, RuV, and VZV.

Characteristic disease state sera are serum samples derived from individuals with specific conditions or diseases. These sera are valuable for many aspects of diagnostics, especially for developing and validating diagnostic tests. For instance, characterized disease state sera ensure that diagnostic tests can reliably and accurately identify individuals with a specific disease while meeting regulatory parameters such as sensitivity, reproducibility, and accuracy. They can also be used as optimization tools, calibration standards, reference materials, and quality control tools.

However, sourcing these sera can be complex and time-consuming, and it can sometimes be impossible to find suitable materials. This is especially true of IgM sera because IgM levels fluctuate during an immune response. Additionally, each disease type has unique variations in IgM levels and characteristics, so expert knowledge is required beforehand.

To address these challenges, Creative Diagnostics has introduced an alternative to hard-to-find human disease state IgM plasma. These human hybrid IgM control Mab materials cover a wide range of diseases, including CMV, HSV, MeV, MuV, RuV, M. pneumoniae, T. gondii, and VZV. The monoclonal antibodies are produced in transgenic mice that express the human IgM heavy chain constant region. The antibodies are then concentrated and added to an IgG-removed and defatted human serum matrix to ensure the final product closely resembles IgM-positive human plasma in the natural disease state. Rigorous testing in ELISA and bead-based applications has shown that the products behave in an almost identical manner to their natural counterparts.

For example, Creative Diagnostics offers Anti-CMV monoclonal antibody (DMAB-CLS25048) to formulate calibrators and controls for CMV IgM assays. Cytomegalovirus (CMV) is widespread, with manifestations ranging from asymptomatic to severe end-organ dysfunction in immunocompromised patients with congenital CMV disease. In addition, Creative Diagnostics provides the Anti-HSV-1/2 monoclonal antibody(DMAB-CLS25049) to prepare calibrators and controls for the HSV-1/2 IgM assay. Herpes simplex virus (HSV), also known as herpes, is a common infection that causes painful blisters or sores. It spreads primarily through skin-to-skin contact, and it is treatable but not curable.

Manufactured under ISO 13485 standards, this new portfolio of antibodies can ensure exceptional quality and reproducibility. Their lot-to-lot consistency and performance will empower laboratory researchers to enhance the accuracy and reliability of their diagnostic tests. Creative Diagnostics can now provide clients a stable, high-performance, and ethically sourced supply of control materials.

For more information about the Human Hybrid IgM Control Monoclonal Antibodies or other other research tools, please visit https://www.creative-diagnostics.com/new-human-hybrid-igm-control-monoclonal-antibody.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.

Thomas Schmitt
Creative Diagnostics
email us here
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.